Investment Review day 2 of 50: Nano-X Imaging $NNOX
This med-tech innovator is disrupting the x-ray market with a far smaller, more portable device. 510(k) FDA clearance in May ’23 was a major turning point.
Initially a 0.5% long-shot bet in 2021, Nano-X was heading for the ‘Theranos’ pile. FDA news derisked the investment substantially, though commercial success is far from guaranteed. I added to my position.
My ‘venture’ sub-portfolio takes small stakes in many high-risk companies. Most will fail, but the rare 100x return justifies the approach. Could Nano-X be one of those winners? Time will tell!
What other companies are transforming healthcare?
—
I’m putting my holdings under the microscope. Over the next 50 days I’ll break down my whole investment portfolio. Wins, losses, and the ‘why’ behind it all. And on day 50 I’m going to share the full portfolio! Follow me and let’s learn together! #StockAnalysis #50daychallenge #investing #medtech
